| Literature DB >> 35056122 |
Abstract
Diabetes is a metabolic disease that affected 9.3% of adults worldwide in 2019. Its co-occurrence is suspected to increase mortality from COVID-19. The treatment of diabetes is mainly based on the long-term use of pharmacological agents, often expensive and causing unpleasant side effects. There is an alarming increase in the number of pharmaceuticals taken in Europe. The aim of this paper is to concisely collect information concerning the few antidiabetic or hypoglycaemic raw plant materials that are present in the consciousness of Europeans and relatively easily accessible to them on the market and sometimes even grown on European plantations. The following raw materials are discussed in this mini-review: Morus alba L., Cinnamomum zeylanicum J.Presl, Trigonella foenum-graecum L., Phaseolus vulgaris L., Zingiber officinale Rosc., and Panax ginseng C.A.Meyer in terms of scientifically tested antidiabetic activity and the presence of characteristic biologically active compounds and their specific properties, including antioxidant properties. The characteristics of these raw materials are based on in vitro as well as in vivo studies: on animals and in clinical studies. In addition, for each plant, the possibility to use certain morphological elements in the light of EFSA legislation is given.Entities:
Keywords: antidiabetic; cinnamon; common bean; diabetes; fenugreek; ginger; ginseng; hypoglycaemic activity; medicinal plants; white mulberry
Year: 2022 PMID: 35056122 PMCID: PMC8778315 DOI: 10.3390/ph15010065
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Different possible ways of introducing medicinal plants into the diet.
| How Can the Medicinal Plant Be Introduced into the Diet? | ||
|---|---|---|
| First way | ||
| Eat on your own | Basic form: | whole leaves |
| whole seeds | ||
| whole shoots | ||
| whole fruits | ||
| Modified form: | ground | |
| crushed | ||
| dried | ||
| cut | ||
| Changed state of matter: | brew | |
| tea | ||
| extract | ||
| Second way | ||
| Change the matrix | Functional food products | |
| Dietary supplements | ||
The most common biologically active compounds identified as probably antidiabetic in medicinal plants.
| Medicinal Plant | Biologically Active Compound Probably Responsible for the Antidiabetic Activity | Main Antidiabetic Mechanism of Action on Organism | Source | |
|---|---|---|---|---|
| White mulberry | 1.5-dideoxy-1.5-imino- |
| inhibition of α-amylase; | [ |
| morin |
| [ | ||
| Fenugreek | galactomannans | - | decrease | [ |
| 4-hydroxyisoleucine |
| [ | ||
| saponins | - | [ | ||
| trigonelline + |
| [ | ||
| Ceylon cinnamon | methylhydroxychalcone polymer | - | elevation in plasma insulin; hypoglycaemic; hypocholesterolemic; | [ |
| cinnamaldehyde |
| [ | ||
| eugenol |
| [ | ||
| Ginger | shogaol |
| increase insulin level; | [ |
| gingerol |
| [ | ||
| Common bean | phaseolamin | - | hypoglycaemic; | [ |
| Ginseng | ginsenoside Rg1 |
| lowering blood glucose level; slows down glucose absorption; obesity reduction; increase in the expression of GLUT-1 and GLUT-4 | [ |
| ginsenoside C-K |
| [ | ||
| ginsenoside Rg3 |
| [ | ||
| ginsenoside Rb1 |
| [ | ||
Source of chemical structures in this table: sigmaaldrich.com accessed on 13 December 2021 [72].
Medicinal plants status according to EFSA legislation [104].
| Medicinal Plant | Morphological Element | Registered as Novel Food |
|---|---|---|
| fruits | NO | |
| young leaves | N/A | |
| stems | N/A | |
| rhizome (root bark) | N/A | |
| root | N/A | |
| twigs | N/A | |
| seeds | NO | |
| leaves | N/A | |
| bark of the branches | NO | |
| leaves | NO | |
| oil of the leaves | N/A | |
| flowers | N/A | |
| seeds | NO | |
| pods | NO | |
| rhizome | NO | |
| root | NO | |
| berries | NO | |
| leaves | NO | |
| oil | NO |
YES—element has not been used as food in European Union before 15 May 1997 and has a safety assessment status; NO—element has been used as food in European Union before 15 May 1997 and does not need safety assessment; N/A—there was no request or a request has not been processed yet; *—exceptions.
Figure 1The ways in which the active ingredients in ginger affect glycaemic control [158].
Some studies considering medicinal plants, as described in this mini review.
| Medicinal Plants | Effective Dose, Intake Duration, and Form of Plant Material | Effects of Consumption in In Vivo Models | Source |
|---|---|---|---|
| 20 mg/100 g b.w./d|5 w|leaf extract | R: FBG reduction (5%) | [ | |
| 0.8 g and 1.2 g|single dose|leaf powder enriched with DNJ (1.5%) | H: PPG60min, PPG90min inhibition, insulin secretion inhibition | [ | |
| 100 mL (1 g of leaves)|tea | R: inhibition of α- glucosidase activity | [ | |
| 400 mg/kg b.w.|7 w|fruits (polysaccharides) | R: FBG reduction (31.9–47.5%), FSI reduction (3.41–4.19 mIU/L), OGTT reduction (18.12–19.30) | [ | |
| 6 g/kg b.w.|28 d|leaves with oat bran (1:1) | M: FBG reduction, PPG60min reduction, aspartate transaminase inhibition, alanine transaminase inhibition | [ | |
| 20 mg and 40 mg and 80 mg/kg|4 w|DNJ extracted from leaves | M: BG reduction, b.w. reduction, SI reduction, HOMA-IR index reduction | [ | |
| 30 mg/kg b.w.|4 w|morin from leaves | R: downregulation of PERK-eIF2α-ATF4 pathway, BG reduction (69.42%) | [ | |
| 600 mg/kg b.w./d|6 w| ethanolic leaf extract or leaf powder | R: FBG reduction, TC reduction, TG reduction, LDL reduction; leaf powder more effective than leaf extract | [ | |
| 2 g/kg b.w./d|4 w|leaf extract | R: FBG reduction, OGTT reduction, HOMA-IR reduction, TC reduction, TG reduction, LDL reduction, insulin resistance improved | [ | |
| 50 mg/d|30 d|seed powder solution | H: TC reduction (13.6%), TG reduction (23,53%), LDL reduction (23,4%), HDL improved (21.7%) | [ | |
| 50 mg/kg b.w./d|6 d|4-hydroxyisoleucine | R: BG reduction (from 163.5 mg/dL to 143.6 mg/dL), FSI reduction (from 1.96 ng/mL to 1.52 ng/mL), glucose tolerance improved | [ | |
| 0.25 g and 0.5 g/kg b.w./d|14 d|ethanolic seeds extract | R: serum glucose reduction (similar to glibenclamide effect), TG reduction, TC reduction, b.w. reduction (5.5% and 9.5%) | [ | |
| 100 mg/kg b.w./d|4 w|fenugreek extract | R: BG reduction, level of liver enzymes (aspartate aminotransferase and alanine aminotransferase) reduction, TG reduction | [ | |
| 500 mg/d|30 d or 60 d or 90 d|seed extract enriched with 40% furostanolic saponins | H: FBG reduction (6.69%, 10.31%, 21.98%); PPG60min (13.7%, 20.6%, 30.4%); HbA1c reduction | [ | |
| 1000 mg/d|12 w|seed extract | H: FBG reduction (24.62%), HbA1c reduction (9.38%); TC reduction (5.66%), TG reduction (17.23%), LDL reduction (4.15%) | [ | |
| 5 mg and 10 mg and 20 mg/kg b.w./d|45 d |cinnamaldehyde | R: BG reduction (60.8, 139.3 and 219.0 mg/dL) | [ | |
| 200 mg/kg b.w./w|4 w|ethanolic extract | R: BG reduction (from 257 mg/dL to 122.9 mg/dL), HbA1c reduction (2.51%) | [ | |
| 1 g/d|90 d| cinnamon supplement | H: PPG90min reduced to 224 mg/dL (with cinnamon) vs. reduced to 270 mg/dL (without cinnamon) | [ | |
| 3000 mg/d|8 w|cinnamon powder | H: SI reduction (by 12.87 mIU/L), FBG reduction (by 0.45 mg/dL) | [ | |
| 25 mg and 50 mg and 100 mg and 200 mg/kg b.w./d|single dose|aqueous extract | R: edemas reduction, NOx reduction similar to indomethacin | [ | |
| 4 mL/kg b.w./d|6 w|ginger juice | R: flattening BG curve, flattening the insulinemia curve | [ | |
| 100–500 mg/kg b.w./d|30 d|aqueous ginger extract | R: activity of glycolytic enzymes improved | [ | |
| 200 mg/kg b.w./d|30 d|ethanolic ginger extract | R: reversed hyperglycaemia, activity of extra-mitochondrial and intra-mitochondrial enzymes improved | [ | |
| 1800 mg/d|8w|dried ginger | H: BMI reduction (0.54 kg/m2), HbA1c (1.11%), FBG (51.15 mg/dL), FSI (7.88 mIU/L), TC (31.10 mg/dL), LDL (17.70 mg/dL) | [ | |
| 2 g/d|12 w|ginger powder | H: FBG reduction (19,41 mg/dL); HbA1c reduction (0.77%); apolipoprotein B reduction (12.45 mg/dL) | [ | |
| 3 g/d|12 w|ginger powder | H: serum glucose reduction (19.41 mg/dL), HbA1c (0.77%), SI reduction (1.46 µIU/mL), insulin resistance reduction (16.38); high-sensitive CRP reduction (2.78 mg/dL) | [ | |
| 2 g/d|8 w|ginger powder | H: SI reduction (13µU/mL), LDL reduction (13.7%), TG reduction (11.7%), HOMA-IR reduction (8.1%) | [ | |
| 200 mg and 400 mg/kg b.w./d|28 d|aqueous ginger extract | R: GLUT-4 in skeletal muscles increase | [ | |
| 100 mg/kg b.w./d|2 w or 4 w|cooked common bean | R: FBG reduction (25% or 35%) | [ | |
| 50 mg and 100 mg and 200 mg and 250 mg/kg b.w./d|40 d|aqueous bean extract | R: FBG reduction (25% or 50%), TC reduction, TG reduction | [ | |
| 300 mg/kg b.w./d|single dose|bean | R: dose of glibenclamide reduction to improve glycaemia | [ | |
| 1500–3000 mg/d|8 w|vinegar ginseng extract | H: HbA1c reduction (0.29–0.56%), FBG reduction (6.76–21.4 mg/dL) compared to placebo | [ | |
| 2 capsules/d|8 w|30% of hydrolyzed ginseng extract | H: FBG reduction, PPG60min | [ | |
| 2.7 g/d|4 w|fermented ginseng | H: PPG120min reduction (17.2%), glucose curve flattened (27.4%), no effect on FBG | [ | |
| 6 g/d|12 w|ginseng | H: no effect on SI level, no effect on insulin sensitivity | [ | |
| 6 g/d|8 w|ginseng | H: obesity level reduced | [ |
W—weeks, d—days, R—rats, M—mice, H—humans, Rb—rabbits, b.w.—body weight, NOx—nitrogen oxides.